In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line

References

• Parkin DM. Global cancer statistics in the year. Lancet Oncol 2000; 2: 533–43
   Web of Science ®Google Scholar
• Ozer H, Diasio RB. Perspectives in the treatment of colorectal cancer. Semin Oncol 2004; 31: 14–8
   PubMedGoogle Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–8
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer–a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15: 368–81
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282–92
   PubMed Web of Science ®Google Scholar
• Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407–12
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–7
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136–47
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47
   PubMed Web of Science ®Google Scholar
• Sorbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31–8
   PubMedGoogle Scholar
• Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003; 10: 1663–82
   PubMed Web of Science ®Google Scholar
• Carde P, Laval F. Effect of cis-dichlorodiammine platinum II and X rays on mammalian cell survival. Int J Radiat Oncol Biol Phys 1981; 7: 929–33
   PubMed Web of Science ®Google Scholar
• Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987; 13: 403–26
   PubMed Web of Science ®Google Scholar
• Hess S, Blackstock W. Oxalipaltin: In vitro and In Vivo Evidence of its Radiation Sensitizing Activity-Pre-Clinical Observations Relevant to Ongoing Clinical Trials. 91st annual meeting of the American Association for Cancer research. Vol 2000; 41: 335
   Google Scholar
• Cividalli A, Ceciarelli F, Livdi E, Altavista P, Cruciani G, Marchetti P, et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002; 52: 1092–8
   PubMedGoogle Scholar
• Freyer G, Bossard N, Romestaing P, Mornex F, Chapet O, Trillet-Lenoir V, et al. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 2001; 19: 2433–8
   PubMed Web of Science ®Google Scholar
• Johnsson, A, Kjellén, E. Early experience of long term radiotherapy combined with oxaliplatin, 5-FU and leucovorin in locally advanced rectal cancer. European Society for Medical Oncology annual meeting; 1992. p. 323.
   Google Scholar
• Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999; 59: 8–13
   PubMed Web of Science ®Google Scholar
• Stickel F, Jungert B, Brueckl V, Schirner I, Brueckl WM, Mannlein G, et al. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anticancer Drugs 2003; 14: 745–9
   PubMed Web of Science ®Google Scholar
• Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 1987; 47: 943–6
   PubMed Web of Science ®Google Scholar
• Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992; 50: 604–10
   PubMed Web of Science ®Google Scholar
• Fischel JL, Etienne MC, Formento P, Milano G. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 1998; 4: 2529–35
   PubMed Web of Science ®Google Scholar
• Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8: 876–85
   PubMed Web of Science ®Google Scholar
• Esaki T, Nakano S, Tatsumoto T, Kuroki-Migita M, Mitsugi K, Nakamura M, et al. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 1992; 52: 6501–6
   PubMed Web of Science ®Google Scholar
• Balart J, Capella G, de los Inocentes RM, de Andres J, Ares C, Craven-Bartle J, et al. Treatment with 5-fluorouracil enhances radiosensitivity of the human pancreatic cancer cell line MiaPaCa-2. Pancreatology 2002; 2: 40–5
   PubMedGoogle Scholar
• Smith TA, Maisey NR, Titley JC, Jackson LE, Leach MO, Ronen SM. Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport. J Nucl Med 2000; 41: 1753–9
   PubMedGoogle Scholar
• Riccardi A, Ferlini C, Meco D, Mastrangelo R, Scambia G, Riccardi R. Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur J Cancer 1999; 35: 86–90
   PubMed Web of Science ®Google Scholar
• Banasiak D, Barnetson AR, Odell RA, Mamegham H, Russell PJ. Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. Radiat Oncol Investig 1999; 7: 77–85
   PubMedGoogle Scholar